Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Rearranged during transfection (RET) gene fusions, occurring in 1% to 2% of NSCLC, have emerged as an oncogenic druggable target. Systemic targ...

Full description

Bibliographic Details
Main Authors: Elisa De Carlo, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
NSCLC
RET fusion
RET inhibitors
next-generation sequencing
selpercatinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1307458/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1307458/full

Similar Items